small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (493)
  • Capabilities (82)
  • Experience (189)
  • Insights & News (5,224)
  • Other Results (127)

Professionals 493 results

T. Reed Stephens
T. Reed Stephens
Partner
  • Washington, DC
Email
+1 202-282-5795
vCard

Partner

  • Washington, DC
Charlie Papavizas
Charlie Papavizas
Partner
  • Washington, DC
Email
+1 202-282-5732
vCard

Partner

  • Washington, DC
Cari Stinebower
Cari Stinebower
Partner
  • Washington, DC
Email
+1 202-282-5788
vCard

Partner

  • Washington, DC
View All Professionals

Capabilities 82 results

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Practice Area

Government Program Fraud, False Claims Act & Qui Tam Litigation

Investigations and litigation involving alleged fraud against the government pose a significant and growing threat to organizations and individuals across all industries that engage directly or indirectly in business with federal, state, and/or local governments. The government makes aggressive use of its extensive criminal and civil investigatory powers to root out alleged fraud and abuse implicating government funds, including one of its most powerful civil enforcement tools—the federal False Claims Act (FCA)—and similar state false claims statutes....Read more

Experience 189 results

Experience

|

September 9, 2025

Greenland Exploration Limited enters business combination with Pelican Acquisition Corporation and March GL Company

Winston & Strawn LLP represented Greenland Exploration Limited in a landmark business combination with Pelican Acquisition Corporation (NASDAQ: PELI) and March GL Company. The transaction, structured as a merger agreement, will result in the formation of Greenland Energy Company, expected to be publicly listed on NASDAQ under the ticker symbol “GLND.” Winston advised Greenland Exploration on all aspects of the deal, including regulatory strategy, corporate structuring, and negotiation of the merger terms....Read more

Experience

|

August 19, 2025

Winston Advised Ellipsis Onshore Holdings in the Acquisition of Oil and Gas Non-Operated Assets in the Permian Basin of Texas and New Mexico

Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets....Read more

Experience

|

May 27, 2025

PicoCELA Inc. Closes $1.8 Public Offering

Winston & Strawn represented Revere Securities LLC acted as the lead placement agent in connection with PicoCELA, Inc. in the closing of its public offering of 6,100,000 American Depositary Shares ("ADSs") at a public placement price of $0.30 per ADS. PicoCELA, Inc. received an aggregate gross proceeds of $1.83 million before deducting placement agent commission and other offering expenses. Each ADS represents one common share of the Company....Read more
View All Experience

Insights & News 5,224 results

Webinar

|

September 30, 2025

Tax Implications of the Big Beautiful Bill Act

Please join us for an engaging and informative webinar led by our experienced tax attorneys as they break down the most significant tax changes introduced by the recently enacted One Big Beautiful Bill Act of 2025, signed into law on July 4, 2025....Read more

Global Trade & Foreign Policy Insights

|

September 26, 2025

|

3 Min Read

USMCA at a Crossroads: Stakeholders Invited to Shape the Future

The Office of the United States Trade Representative (USTR) has initiated a public consultation process in preparation for the upcoming joint review of the United States–Mexico–Canada Agreement (USMCA), scheduled for July 1, 2026. This process is mandated by Article 34.7 of the USMCA and section 611 of the USMCA Implementation Act, which require a comprehensive evaluation of the agreement’s operation and a determination by each party on whether to extend the agreement for an additional 16-year term.

Capital Markets & Securities Law Watch

|

September 25, 2025

|

5 Min Read

SEC Issues Policy Statement on Mandatory Arbitration Provisions and Acceleration of Registration Statement Effectiveness

On September 17, 2025, the Securities and Exchange Commission (SEC or the Commission) released a policy statement (the Policy Statement) addressing its approach to mandatory arbitration provisions in the governing documents of companies intending to go public (each, an Issuer).

View All Insights & News

Other Results 127 results

Site Content

The Corporate Transparency Act
Task Force

Site Content

What Is The Jones Act?

The Jones Act, as used in the world of shipping is a law that reserves the transportation of goods between two points in the United States to qualified U.S.-flag vessels. This coastwise reservation law is named after its chief sponsor, Senator Wesley L. Jones. Similar laws apply to the transportation of passengers and reserve towing, dredging, and fishing in U.S. waters to qualified U.S.-flag vessels. Such vessels must be U.S. citizen-owned, U.S. citizen-crewed, U.S.-registered, and U.S.-built. Another law, also called the “Jones Act,” relates to merchant mariner injury recoveries....Read more

Site Content

What Is the Securities Act of 1933?

The Securities Act of 1933 (as amended, the “Securities Act”) was passed to ensure that investors have financial and other important information about securities that are being sold publicly. It also bans the use of fraud, deceit, and misrepresentation in the sales of securities. The Securities Act, which is also referred to as the “truth in securities” law, is part of a legislative effort to govern and oversee the securities industry....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising